文献速递糖尿病肥胖与代谢综合征

二十年间种族化群体在2型糖尿病随机临床试验中的参与情况:一项元流行病学综述

Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review.
PubMed 文献 · Diabetologia · 2024-01-04

该元流行病学综述检索2000年1月1日至2020年12月31日Ovid MEDLINE,纳入83项2型糖尿病药物随机对照试验(283,122名参与者),比较种族化与白人参与者的参与-患病率比(PPR)。政府资助试验中种族化人群PPR为0.72(95%CI 0.60, 0.86),产业资助试验中为0.36(95%CI 0.32, 0.42),均提示代表性不足。

要点

  • 政府资助试验中种族化参与者PPR为0.72(95%CI 0.60, 0.86),低于0.80的不足阈值。
  • 产业资助试验中种族化参与者PPR为0.36(95%CI 0.32, 0.42),代表性不足更明显。
  • 白人参与者在政府资助试验中PPR为1.11(95%CI 0.99, 1.24),在产业资助试验中为1.95(95%CI 1.74, 2.18)。

核心结论

  • 种族化参与者在政府资助和产业资助的2型糖尿病试验中均代表性不足。
  • 应制定策略改善种族化参与者招募和入组随机对照试验。

研究设计与样本

  • 元流行病学综述,检索Ovid MEDLINE 2000年1月1日至2020年12月31日。
  • 纳入83项2型糖尿病药物随机对照试验,共283,122名参与者,其中政府资助15项、产业资助68项。
  • 纳入标准为样本量至少100名参与者且全部为成人2型糖尿病;产业资助试验须在至少两个国家招募。
  • 计算每项试验的参与-患病率比(PPR),采用随机效应荟萃分析生成汇总PPR及95%CI。
  • PPR<0.80表示代表性不足,PPR>1.20表示过度代表。

主要发现

  • 政府资助试验中,白人参与者PPR为1.11(95%CI 0.99, 1.24),种族化参与者PPR为0.72(95%CI 0.60, 0.86)。
  • 产业资助试验中,白人参与者PPR为1.95(95%CI 1.74, 2.18),种族化参与者PPR为0.36(95%CI 0.32, 0.42)。

关键数值与推荐

  • PPR<0.80定义为代表性不足,PPR>1.20定义为过度代表。
  • 政府资助试验种族化参与者PPR 0.72(95%CI 0.60, 0.86)。
  • 产业资助试验种族化参与者PPR 0.36(95%CI 0.32, 0.42)。

局限性

  • 依赖研究者报告的族裔和种族将参与者分类为「白人」或「种族化」。
  • 使用了2型糖尿病患病率和人口学数据的估计值。
  • 汇总估计存在高度异质性。
  • 尽管有上述局限性,结果在方向上保持一致。
  • 本研究未进行偏倚风险评估,因目标为考察招募情况而非评估临床试验结局的可信度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes mellitus prevalence is increasing globally and the greatest burden is borne by racialised people. However, there are concerns that the enrolment of racialised people into RCTs is limited, resulting in a lack of ethnic and racial diversity. This may differ depending whether an RCT is government funded or industry funded. The aim of this study was to review the proportions of racialised and white participants included in large RCTs of type 2 diabetes pharmacotherapies relative to the disease burden of type 2 diabetes in these groups. METHODS: The Ovid MEDLINE database was searched from 1 January 2000 to 31 December 2020. English language reports of RCTs of type 2 diabetes pharmacotherapies published in select medical journals were included. Studies were included in this review if they had a sample size of at least 100 participants and all participants were adults with type 2 diabetes. Industry-funded trials must have recruited participants from at least two countries. Government-funded trials were not held to the same standard because they are typically conducted in a single country. Data including the numbers and proportions of participants by ethnicity and race were extracted from trial reports. The participation-to-prevalence ratio (PPR) was calculated for each trial by dividing the percentage of white and racialised participants in each trial by the percentage of white and racialised participants with type 2 diabetes, respectively, for the regions of recruitment. A random-effects meta-analysis was used to generate the pooled PPRs and 95% CIs across study types. A PPR <0.80 indicates under-representation and a PPR >1.20 indicates over-representation. Risk of bias assessments were not conducted for this study as the objective was to examine recruitment of racialised and white participants rather than evaluate the trustworthiness of clinical trial outcomes. RESULTS: A total of 83 trials were included, involving 283,122 participants, of which 15 were government-funded and 68 were industry-funded trials. In government-funded trials, the PPR for white participants was 1.11 (95% CI 0.99, 1.24) and the PPR for racialised participants was 0.72 (95% CI 0.60, 0.86). In industry-funded trials, the PPR for white participants was 1.95 (95% CI 1.74, 2.18) and the PPR for racialised participants was 0.36 (95% CI 0.32, 0.42). The limitations of this study include the reliance on investigator-reported ethnicity and race to classify participants as 'white' or 'racialised', the use of estimates for type 2 diabetes prevalence and demographic data, and the high levels of heterogeneity of pooled estimates. However, despite these limitations, the results were consistent with respect to direction. CONCLUSIONS/INTERPRETATION: Racialised participants are under-represented in government- and industry-funded type 2 diabetes trials. Strategies to improve recruitment and enrolment of racialised participants into RCTs should be developed. REGISTRATION: Open Science Framework registration no. f59mk ( https://osf.io/f59mk ) FUNDING: The authors received no financial support for this research or authorship of the article.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Ahmed R, de Souza RJ, Li V, et al. Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review. Diabetologia. 2024. PMID: 38177564. doi:10.1007/s00125-023-06052-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。